Handisurya Alessandra, Gilch Sabine, Winter Dorian, Shafti-Keramat Saeed, Maurer Dieter, Schätzl Hermann M, Kirnbauer Reinhard
Laboratory of Viral Oncology, DIAID, Department of Dermatology, Medical University Vienna, Austria.
FEBS J. 2007 Apr;274(7):1747-58. doi: 10.1111/j.1742-4658.2007.05721.x. Epub 2007 Feb 20.
Prion diseases are fatal neurodegenerative disorders caused by proteinaceous infectious pathogens termed prions (PrP(Sc)). To date, there is no prophylaxis or therapy available for these transmissible encephalopathies. Passive immunization with monclonal antibodies recognizing the normal host-encoded prion protein (PrP(C)) has been reported to abolish PrP(Sc) infectivity and to delay onset of disease. Because of established immunologic tolerance against the widely expressed PrP(C), active immunization appears to be difficult to achieve. To overcome this limitation, papillomavirus-like particles were generated that display a nine amino acid B-cell epitope, DWEDRYYRE, of the murine/rat prion protein in an immunogenic capsid surface loop, by insertion into the L1 major capsid protein of bovine papillomavirus type 1. The PrP peptide was selected on the basis of its previously suggested central role in prion pathogenesis. Immunization with PrP-virus-like particles induced high-titer antibodies to PrP in rabbit and in rat, without inducing overt adverse effects. As determined by peptide-specific ELISA, rabbit immune sera recognized the inserted murine/rat epitope and also cross-reacted with the homologous rabbit/human epitope differing in one amino acid residue. In contrast, rat immune sera recognized the murine/rat peptide only. Sera of both species reacted with PrP(C) in its native conformation in mouse brain and on rat pheochromocytoma cells, as determined by immunoprecipitation and fluorescence-activated cell sorting analysis. Importantly, rabbit anti-PrP serum contained high-affinity antibody that inhibited de novo synthesis of PrP(Sc) in prion-infected cells. If also effective in vivo, PrP-virus-like particle vaccination opens a unique possibility for immunologic prevention of currently fatal and incurable prion-mediated diseases.
朊病毒疾病是由称为朊病毒(PrP(Sc))的蛋白质传染性病原体引起的致命性神经退行性疾病。迄今为止,尚无针对这些传染性脑病的预防或治疗方法。据报道,用识别正常宿主编码的朊病毒蛋白(PrP(C))的单克隆抗体进行被动免疫可消除PrP(Sc)的传染性并延缓疾病发作。由于对广泛表达的PrP(C)已建立免疫耐受,主动免疫似乎难以实现。为克服这一限制,通过将一个九氨基酸的B细胞表位DWEDRYYRE插入牛乳头瘤病毒1型的L1主要衣壳蛋白中,在免疫原性衣壳表面环中展示鼠/大鼠朊病毒蛋白,从而产生了乳头瘤病毒样颗粒。选择PrP肽是基于其先前在朊病毒发病机制中所提示的核心作用。用PrP病毒样颗粒免疫可在兔和大鼠中诱导出高滴度的抗PrP抗体,且未引起明显的不良反应。通过肽特异性ELISA测定,兔免疫血清识别插入的鼠/大鼠表位,并且还与在一个氨基酸残基上不同的同源兔/人表位发生交叉反应。相比之下,大鼠免疫血清仅识别鼠/大鼠肽。通过免疫沉淀和荧光激活细胞分选分析确定,两种动物的血清均与小鼠脑中和大鼠嗜铬细胞瘤细胞中天然构象的PrP(C)发生反应。重要的是,兔抗PrP血清含有高亲和力抗体,可抑制朊病毒感染细胞中PrP(Sc)的从头合成。如果在体内也有效,PrP病毒样颗粒疫苗接种为目前致命且无法治愈的朊病毒介导疾病的免疫预防开辟了独特的可能性。